Reduced glucose effectiveness associated with reduced insulin release: an artifact of the minimal-model method.

We previously demonstrated that minimal model-derived estimates of glucose effectiveness (SG), based on the frequently sampled intravenous glucose tolerance test (SGFSIGT), were reduced in islet-transplanted or streptozotocin-treated dogs and in patients with insulin-dependent diabetes mellitus. To ascertain the validity of our observations, we compared SGFSIGT with estimates based on a basal hormone replacement glucose clamp (SGBRCLAMP) and a basal hormone replacement glucose tolerance test (SGBRGTT) in normal control (CNTL, n = 12) and streptozotocin-treated dogs with normal fasting plasma glucose (STZ-Rx, n = 9). SGFSIGT was reduced in STZ-Rx compared with CNTL (P < 0.05). However, neither SGBRCLAMP nor SGBRGTT was reduced in the STZ-Rx group (P > 0.05). Comparison of protocols for each subject indicated that SGFSIGT was greater than either SGBRCLAMP or SGBRGTT in control (P < 0.002) but not in STZ-Rx dogs (P > 0.1). The relationship of SGFSIGT to insulin secretory function suggests that our previous conclusion that SGFSIGT was reduced in subjects with limited insulin release may be an artifact of the minimal-model method. Our results suggest that caution must be exercised in the interpretation of differences in minimal-model estimates of SG between subject groups with significantly different levels of insulin secretory function.

[1]  R N Bergman,et al.  Estimation of Endogenous Glucose Production During Hyperinsulinemic-Euglycemic Glucose Clamps: Comparison of Unlabeled and Labeled Exogenous Glucose Infusates , 1987, Diabetes.

[2]  R N Bergman,et al.  MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. , 1986, Computer methods and programs in biomedicine.

[3]  I. Godsland,et al.  Associations between insulin sensitivity, and free fatty acid and triglyceride metabolism independent of uncomplicated obesity. , 1994, Metabolism: clinical and experimental.

[4]  R N Bergman,et al.  Importance of Glucose Per Se to Intravenous Glucose Tolerance: Comparison of the Minimal-Model Prediction with Direct Measurements , 1985, Diabetes.

[5]  D. Owens,et al.  Comparison of Estimates of Insulin Sensitivity From Minimal Model Analysis of the Insulin-Modified Frequently Sampled Intravenous Glucose Tolerance Test and the Isoglycemic Hyperinsulinemic Clamp in Subjects With NIDDM , 1995, Diabetes.

[6]  R N Bergman,et al.  The Insulin Sensitivity Index: Correlation in Dogs Between Values Determined from the Intravenous Glucose Tolerance Test and the Euglycemic Glucose Clamp , 1984, Diabetes.

[7]  R. Bergman,et al.  Modeling Error and Apparent Isotope Discrimination Confound Estimation of Endogenous Glucose Production During Euglycemic Glucose Clamps , 1988, Diabetes.

[8]  C Cobelli,et al.  Minimal Models of Glucose Disappearance: Lessons from the Labelled IVGTT , 1991, Diabetic medicine : a journal of the British Diabetic Association.

[9]  R N Bergman,et al.  Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. , 1987, The Journal of clinical investigation.

[10]  I. Hramiak,et al.  A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. , 1990, The Journal of clinical endocrinology and metabolism.

[11]  R. Bergman,et al.  Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose. , 1990, The Journal of clinical endocrinology and metabolism.

[12]  R N Bergman,et al.  The Insulin Sensitivity Index in Nondiabetic Man: Correlation Between Clamp-derived and IVGTT-derived Values , 1986, Diabetes.

[13]  R N Bergman,et al.  Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. , 1990, The Journal of clinical endocrinology and metabolism.

[14]  S. Kahn,et al.  Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. , 1994, The Journal of clinical investigation.

[15]  K. Tokuyama,et al.  Insulin sensitivity, insulin secretion, and glucose effectiveness in anorexia nervosa: a minimal model analysis. , 1993, Metabolism: clinical and experimental.

[16]  H. Imura,et al.  Insulin sensitivity, insulin secretion, and glucose effectiveness in subjects with impaired glucose tolerance: a minimal model analysis. , 1994, Metabolism: clinical and experimental.

[17]  D. Finegood,et al.  Insulin Sensitivity and Glucose Effectiveness in Long-Term Islet-Autotransplanted Dogs , 1989, Diabetes.

[18]  D. Finegood,et al.  Reduced Insulin Secretion by Repeated Low Doses of STZ Impairs Glucose Effectiveness but Does Not Induce Insulin Resistance in Dogs , 1993, Diabetes.